Jun 2026 (Q2 FY26) — Aug 6, 2026
Oscar Health Q2 FY26 — Record Profitability and Raised Full-Year Outlook
Read the full callOscar Health (OSCR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Oscar Health earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 4,880 | +70.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 8.0 | +16.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 362 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$32.54 +2.04% · +$0.65
Performance +67.8% 1Y
1Y: $19.39 on 17 Oct 2025 → $32.54. High $34.32 (14 Oct 2026), low $10.85 (30 Mar 2026).
- Previous close
- $31.89
- 52-week range
- $10.85 – $34.32
- One year
- +61.25%
Overview
- Symbol
- OSCR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Oscar Health Q1 FY26 — Strong Growth and Profitability Driven by Tech and Disciplined Execution
Read the full callEvery analysed call
Oscar Health earnings calls (OSCR)
Financials
What the filings say
Net profit, year on year: +258% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,423 | 2,392 | 3,046 | 2,864 | 2,986 | 2,805 | 4,647 | 4,880 |
| Operating profit | -48 | -148 | 297 | -230 | -129 | -334 | 704 | 389 |
| Operating margin | −2.0% | −6.2% | 9.8% | −8.1% | −4.3% | −11.9% | 15.2% | 8.0% |
| Other income | 2 | 0 | -3 | 3 | -3 | -20 | 0 | -1 |
| Interest | 6 | 6 | 6 | 6 | 7 | -1 | 5 | 5 |
| Profit before tax | -52 | -154 | 288 | -234 | -139 | -353 | 699 | 383 |
| Tax rate | −4.0% | 0.3% | 4.4% | 2.2% | 1.3% | 0.1% | 2.8% | 5.5% |
| Net profit | -55 | -154 | 275 | -228 | -137 | -353 | 679 | 362 |
| EPS ($ per share) | -0.22 | — | 1.10 | -0.89 | -0.53 | — | 2.28 | 1.20 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | — | — | — | — | — |
| Reserves | — | -1,427 | -2,000 | -2,606 | -2,877 | -2,851 | -3,294 |
| Total liabilities | — | 1,823 | 1,929 | 3,634 | 2,795 | 3,824 | 5,345 |
| Fixed assets | — | 36 | 47 | 60 | 62 | 67 | 88 |
| Investments | — | — | — | — | 690 | 624 | — |
| Total assets | — | 2,272 | 3,322 | 4,527 | 3,601 | 4,840 | 6,325 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -165 | 223 | -182 | 380 | -272 | 978 | 1,095 |
| Cash from investing | 151 | -345 | -775 | -227 | 577 | -1,387 | -241 |
| Cash from financing | -2 | 612 | 1,239 | 301 | 6 | 68 | 399 |
| Net cash flow | -17 | 490 | 282 | 455 | 311 | -341 | 1,253 |
| Capital expenditure | -26 | -14 | -26 | -29 | -26 | -28 | -36 |
| Free cash flow | -191 | 209 | -208 | 351 | -298 | 950 | 1,058 |
OSCR operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Members | 3.2MOscar ended the first quarter with 3.2 million members, an increase of 56% year-over-year.Source: earnings call transcript | 2.96MOscar ended the second quarter with 2.96 million members, up 46% year-over-year.Source: earnings call transcript | -7.5% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
108 filings between Nov 11, 2025 and Sep 18, 2026.
Open market
decisions to buy or sellPurchases
$11.92M
1 purchase by 1 insider
Sales
$150.02M
62 sales by 7 insiders
92% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
- 1
- Tax withheld — shares kept back by the company to cover tax
Also filed: 16 other filings, 13 conversions, 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bertolini Mark T | $11.92M | $70.68M | Jun 30, 2026 |
| Schlosser Mario | — | $68.79M | Sep 3, 2026 |
| Blackley Richard Scott | — | $7.94M | Sep 3, 2026 |
| Liang Janet | — | $821.1K | Sep 3, 2026 |
| WITTMAN VANESSA AMES | — | $806.0K | Sep 18, 2026 |
| McAnaney Adam | — | $783.5K | Sep 3, 2026 |
| Baltrus Victoria | — | $194.5K | Sep 3, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | WITTMAN VANESSA AMES Director | Sale 10b5-1 plan | 25,000 | $806.0K |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 164,218 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 1,323,589 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 6,268,097 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 75,520 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 1,323,589 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 4,855,810 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 164,218 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 4,855,810 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 164,218 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 1,323,589 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 6,268,097 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 4,855,810 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 1,323,589 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 4,855,810 | $0 |
| Sep 18, 2026 | Kushner Joshua Co-Founder and Vice Chairman | Other | 75,520 | $0 |
| Sep 18, 2026 | Thrive Partners II GP, LLC Director | Other | 164,218 | $0 |
| Sep 3, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 31,422 | $988.2K |
| Sep 3, 2026 | Baltrus Victoria Chief Accounting Officer | Sale 10b5-1 plan | 958 | $30.1K |
| Sep 3, 2026 | Blackley Richard Scott Chief Financial Officer | Sale 10b5-1 plan | 28,869 | $907.9K |
| Sep 3, 2026 | Liang Janet President, Oscar Insurance | Sale 10b5-1 plan | 10,360 | $325.8K |
| Sep 3, 2026 | McAnaney Adam Chief Legal Officer | Sale 10b5-1 plan | 9,092 | $285.9K |
| Aug 28, 2026 | Schlosser Mario Director | Sale | 150,000 | $4.62M |
| Aug 28, 2026 | Schlosser Mario Director | Conversion | 150,000 | — |
| Aug 27, 2026 | Schlosser Mario Director | Conversion | 600,000 | — |
| Aug 27, 2026 | Schlosser Mario Director | Sale | 600,000 | $18.20M |
| Aug 18, 2026 | Blackley Richard Scott Chief Financial Officer | Sale | 18,750 | $595.1K |
| Jul 1, 2026 | Schlosser Mario Director | Conversion 10b5-1 plan | 47,500 | — |
| Jul 1, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 3,600 | $106.2K |
| Jul 1, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 30,228 | $956.7K |
| Jul 1, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 13,672 | $421.1K |
| Jun 30, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 488,654 | $13.85M |
| Jun 30, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 135,590 | $3.93M |
| Jun 29, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 58,926 | $1.77M |
| Jun 29, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 555,826 | $16.21M |
| Jun 26, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 441,373 | $12.85M |
| Jun 26, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 149,795 | $4.46M |
| Jun 25, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 597,942 | $17.10M |
| Jun 25, 2026 | Bertolini Mark T Chief Executive Officer | Sale 10b5-1 plan | 17,200 | $500.2K |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 31,912 | $944.0K |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 286,988 | $8.31M |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 97 | $2.9K |
| Jun 23, 2026 | Schlosser Mario Director | Conversion 10b5-1 plan | 880,000 | — |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 15,491 | $448.5K |
| Jun 23, 2026 | Schlosser Mario Director | Conversion 10b5-1 plan | 47,500 | — |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 102 | $3.1K |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 33,592 | $993.7K |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 16,306 | $472.1K |
| Jun 23, 2026 | Schlosser Mario Director | Conversion 10b5-1 plan | 50,000 | — |
| Jun 23, 2026 | Schlosser Mario Director | Sale 10b5-1 plan | 102 | $3.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Oscar Health, Inc.
Free account. Everything above stays public.
Write why you follow Oscar Health, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading